argenx SE

ARGX ·Healthcare, Drug Manufacturers - General
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Operating Activities
Net Income $1.29B $833.0M $-295.1M $-709.6M $-408.3M $-608.5M —
Depreciation & Amortization — — — — — — —
Depreciation — — — — — — —
Amortization — — — — — — —
Stock-Based Compensation $128.0M $147.0M $164.0M $120.0M $171.2M $96.9M $44.2M
Net Cash from Operating Activities $685.2M $-82.7M $-420.3M $-862.8M $-606.8M $-398.5M $151.6M
Investing Activities
Capital Expenditures $6.2M $1.8M $812.0K $837.0K $3.6M $1.1M $1.8M
Business Acquisitions — — — — — — —
Net Cash from Investing Activities $984.0M $-717.6M $308.2M $-461.2M $-347.1M $344.7M $-833.3M
Financing Activities
Dividends Paid — — — — — — —
Stock Repurchases — — — — — — —
Net Cash from Financing Activities $233.0M $279.8M $1.34B $843.8M $1.12B $833.0M $733.7M
Net Change in Cash — — — — — — —
Free Cash Flow $679.0M $-84.5M $-421.1M $-863.6M $-610.4M $-399.5M $149.8M